Vasostatin-1, a chromogranin A (CgA)-derived peptide (76 amino acids), is known to suppress vasoconstriction and angiogenesis. A recent study has shown that vasostatin-1 suppresses the adhesion of human U937 monocytes to human endothelial cells (HECs) via adhesion molecule down-regulation. The present study evaluated the expression of vasostatin-1 in human atherosclerotic lesions and its effects on inflammatory responses in HECs and human THP-1 monocyte-derived macrophages, macrophage foam cell formation, migration and proliferation of human aortic smooth muscle cells (HASMCs) and extracellular matrix (ECM) production by HASMCs, and atherogenesis in apolipoprotein E-deficient (ApoE−/−) mice. Vasostatin-1 was expressed around Monckeberg’s medial calcific sclerosis in human radial arteries. Vasostatin-1 suppressed lipopolysaccharide (LPS)-induced up-regulation of monocyte chemotactic protein-1 (MCP-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin in HECs. Vasostatin-1 suppressed inflammatory M1 phenotype and LPS-induced interleukin-6 (IL-6) secretion via nuclear factor-κB (NF-κB) down-regulation in macrophages. Vasostatin-1 suppressed oxidized low-density lipoprotein (oxLDL)-induced foam cell formation associated with acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) and CD36 down-regulation and ATP-binding cassette transporter A1 (ABCA1) up-regulation in macrophages. In HASMCs, vasostatin-1 suppressed angiotensin II (AngII)-induced migration and collagen-3 and fibronectin expression via decreasing ERK1/2 and p38 phosphorylation, but increased elastin expression and matrix metalloproteinase (MMP)-2 and MMP-9 activities via increasing Akt and JNK phosphorylation. Vasostatin-1 did not affect the proliferation and apoptosis in HASMCs. Four-week infusion of vasostatin-1 suppressed the development of aortic atherosclerotic lesions with reductions in intra-plaque inflammation, macrophage infiltration, and SMC content, and plasma glucose level in ApoE−/− mice. These results indicate the inhibitory effects of vasostatin-1 against atherogenesis. The present study provided the first evidence that vasostatin-1 may serve as a novel therapeutic target for atherosclerosis.
Skip Nav Destination
Article navigation
December 2018
-
Cover Image
Cover Image
Regeneration of the renal vasculature after release of ureteral obstruction. This study by Nagalakshmi et al. shows that partial ureteral obstruction in neonatal mice leads to a significant loss of the renal vasculature, whereas release of obstruction results in remarkable regeneration of the renal arterial tree; for details, see pages 2519–2545 of Clinical Science volume 132, issue 23.
Research Article|
December 05 2018
Inhibitory effects of vasostatin-1 against atherogenesis
Yuki Sato;
Yuki Sato
1Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Search for other works by this author on:
Rena Watanabe;
Rena Watanabe
1Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Search for other works by this author on:
Nozomi Uchiyama;
Nozomi Uchiyama
1Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Search for other works by this author on:
Nana Ozawa;
Nana Ozawa
1Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Search for other works by this author on:
Yui Takahashi;
Yui Takahashi
1Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Search for other works by this author on:
Remina Shirai;
Remina Shirai
1Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Search for other works by this author on:
Kengo Sato;
Kengo Sato
1Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Search for other works by this author on:
Yusaku Mori;
Yusaku Mori
2Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Search for other works by this author on:
Takaaki Matsuyama;
Takaaki Matsuyama
3Department of Legal Medicine, Showa University School of Medicine, Tokyo, Japan
4Department of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan
Search for other works by this author on:
Hatsue Ishibashi-Ueda;
Hatsue Ishibashi-Ueda
4Department of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan
Search for other works by this author on:
Tsutomu Hirano;
Tsutomu Hirano
2Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Search for other works by this author on:
Takuya Watanabe
1Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Correspondence: Takuya Watanabe ([email protected])
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
May 29 2018
Revision Received:
October 11 2018
Accepted:
November 05 2018
Accepted Manuscript online:
November 06 2018
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2018
Clin Sci (Lond) (2018) 132 (23): 2493–2507.
Article history
Received:
May 29 2018
Revision Received:
October 11 2018
Accepted:
November 05 2018
Accepted Manuscript online:
November 06 2018
Citation
Yuki Sato, Rena Watanabe, Nozomi Uchiyama, Nana Ozawa, Yui Takahashi, Remina Shirai, Kengo Sato, Yusaku Mori, Takaaki Matsuyama, Hatsue Ishibashi-Ueda, Tsutomu Hirano, Takuya Watanabe; Inhibitory effects of vasostatin-1 against atherogenesis. Clin Sci (Lond) 12 December 2018; 132 (23): 2493–2507. doi: https://doi.org/10.1042/CS20180451
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |